Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection
Jared Pitts(Gilead Sciences (United States)), John P. Bilello(Global Vaccines (United States)), Xuping Xie(The University of Texas Medical Branch at Galveston), Bill J. Smith(Gilead Sciences (United States)), Xianghan Lu(United States Military Academy), Raju Subramanian(Gilead Sciences (United States)), Diane S. Lye(Gilead Sciences (United States)), Adriana E. Kajon(Lovelace Respiratory Research Institute), Darius Babusis(Gilead Sciences (United States)), Roy Bannister(Gilead Sciences (United States)), Bin Ma(Tongji University), Tomáš Cihlář(Gilead Sciences (United States)), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston), Maria M. Toteva(Gilead Sciences (United States)), Nicholas C. Riola(Gilead Sciences (United States)), Meghan S. Vermillion(Lovelace Respiratory Research Institute), Danielle Porter(Gilead Sciences (United States)), Richard L. Mackman(Gilead Sciences (United States)), Xiaofeng Zhao(Gilead Sciences (United States)), Kim Barrett(Gilead Sciences (United States))
Cited by 13
Related Papers
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k